Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: Primary efficacy and safety outcomes of the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial

被引：0
|
作者：
Lieberman, JA [1 ]
Stroup, TS [1 ]
McEvoy, JP [1 ]
Swartz, MS [1 ]
Rosenheck, RA [1 ]
Perkins, DO [1 ]
Keefe, RS [1 ]
Davis, SM [1 ]
Davis, CE [1 ]
Lebowitz, B [1 ]
Hsiao, J [1 ]
Severe, J [1 ]
机构：
[1] Columbia Univ, New York, NY USA
来源：
NEUROPSYCHOPHARMACOLOGY | 2005年 / 30卷
关键词：
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
引用
收藏
页码：S32 / S32
页数：1
相关论文
共 50 条
  • [1] Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia: Efficacy and Safety Outcomes of the CATIE Trial
    Lieberman, Jeffrey A.
    [J]. CNS SPECTRUMS, 2006, : 8 - 9
  • [2] Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study
    Volavka, Jan
    Czobor, Pal
    Citrome, Leslie
    Van Dorn, Richard A.
    [J]. CNS SPECTRUMS, 2014, 19 (05) : 374 - 381
  • [3] Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial
    Swartz, MS
    Perkins, DO
    Stroup, TS
    McEvoy, JP
    Nieri, JM
    Haak, DC
    [J]. SCHIZOPHRENIA BULLETIN, 2003, 29 (01) : 33 - 43
  • [4] Comparative effectiveness of antipsychotic drugs - A commentary on Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)
    Lieberman, Jeffrey A.
    [J]. ARCHIVES OF GENERAL PSYCHIATRY, 2006, 63 (10) : 1069 - 1072
  • [5] The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: Practical implications of the CATIE schizophrenia trial
    Nasrallah, Henry A.
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2007, 68 : 5 - 11
  • [6] The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: Clinical comparison of subgroups with and without the metabolic syndrome
    Meyer, JM
    Nasrallah, HA
    McEvoy, JP
    Goff, DC
    Davis, SM
    Chakos, M
    Patel, JK
    Keefe, RSE
    Stroup, TS
    Lieberman, JA
    [J]. SCHIZOPHRENIA RESEARCH, 2005, 80 (01) : 9 - 18
  • [7] Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
    Lieberman, JA
    Stroup, TS
    McEvoy, JP
    Swartz, MS
    Rosenheck, RA
    Perkins, DO
    Keefe, RSE
    Davis, SM
    Davis, CE
    Lebowitz, BD
    Severe, J
    Hsiao, JK
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (12): : 1209 - 1223
  • [8] Baseline neurocognitive assessment of 1364 patients with schizophrenia in the clinical antipsychotic trials for intervention effectiveness (CATIE) project
    Keefe, R
    Bilder, RM
    Palmer, B
    Harvey, PD
    Davis, S
    McEvoy, J
    Golberg, T
    Gold, J
    Green, MF
    Swartz, MS
    Stroup, S
    Rosenheck, R
    Perkins, D
    Meltzer, H
    Lieberman, JA
    [J]. BIOLOGICAL PSYCHIATRY, 2005, 57 (08) : 79S - 79S
  • [9] Baseline neurocognitive assessment of 1364 patients with schizophrenia in the clinical antipsychotic trials for intervention effectiveness (CATIE) project
    Keefe, R
    Bilder, RM
    Harvey, PD
    Davis, S
    Palmer, B
    McEvoy, JP
    Goldberg, TE
    Gold, JM
    Green, MR
    Swartz, M
    Stroup, S
    Rosenheck, R
    Perkins, DO
    Meltzer, HY
    Miller, D
    Canive, J
    Walker, TM
    Lieberman, JA
    [J]. SCHIZOPHRENIA BULLETIN, 2005, 31 (02) : 361 - 362
  • [10] Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: Development, methodology, and rationale
    Keefe, RSE
    Mohs, RC
    Bilder, RM
    Harvey, PD
    Green, MF
    Meltzer, HY
    Gold, JM
    Sano, M
    [J]. SCHIZOPHRENIA BULLETIN, 2003, 29 (01) : 45 - 55
12345